The BREAKWATER trial showed significant improvement in progression-free survival with Braftovi, Erbitux, and mFOLFOX6 in mCRC patients with BRAF V600E mutations. Median overall survival was 30.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results